FDA has indicated Gavreto (pralsetinib) from Blueprint Medicines to treat adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC). The drug was formerly known as BLU-667 and won FDA approval in September 2020. CStone, which is developing the drug in China, received approval from that country’s regulatory authority, making it the first novel therapy for…